Cannabinoid influence on cytokine profile in multiple sclerosis

S Katona, E Kaminski, H Sanders, J Zajicek

Research output: Contribution to journalArticlepeer-review

51 Citations (Scopus)


Cannabinoids have been suggested as possessing immunomodulatory properties, and cannabinoid receptors are present on leucocytes. Clinically, there is some evidence that cannabinoids may be therapeutically useful in treating multiple sclerosis, which is generally believed to be an autoimmune condition. This paper reports data derived from the Cannabinoids in MS (CAMS) study, which was the largest randomized controlled trial yet conducted to evaluate the therapeutic efficacy of cannabinoids. We found no evidence for cannabinoid influence on serum levels of interferon (IFN)-gamma, interleukin (IL)-10, IL-12 or C-reactive protein as measured using enzyme-linked immunosorbent assay (ELISA), in comparison to control values. Mitogenic stimulation experiments also failed to demonstrate any significant reduction in percentage of CD3+, IFN-gamma producing cells after exposure to cannabinoids in vivo, although numbers were small. Further work is needed to establish the functional significance of cannabinoid receptors on immune cells.

Original languageEnglish
Pages (from-to)580-5
Number of pages6
JournalClinical and Experimental Immunology
Issue number3
Publication statusPublished - Jun 2005


  • C-Reactive Protein
  • Cannabinoids
  • Cannabis
  • Cells, Cultured
  • Cytokines
  • Double-Blind Method
  • Dronabinol
  • Female
  • Humans
  • Immunologic Factors
  • Interferon-gamma
  • Interleukin-10
  • Interleukin-12
  • Male
  • Middle Aged
  • Multiple Sclerosis
  • Phytotherapy
  • Plant Oils


Dive into the research topics of 'Cannabinoid influence on cytokine profile in multiple sclerosis'. Together they form a unique fingerprint.

Cite this